Cargando…

Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma

Chimeric antigen receptor (CAR) T-cell therapy has exhibited promising clinical outcomes in treating relapsed/refractory (R/R) B-cell hematologic malignancies. Current studies have shown a close correlation between baseline tumor burden and therapeutic response in CAR-T cell therapy. However, the ro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Ruimin, Tan Su Yin, Elaine, Wang, Linqin, Zhao, Xin, Zhou, Linghui, Wang, Guangfa, Zhang, Mingming, Zhao, Houli, Wei, Guoqing, Wang, Yiyun, Wu, Wenjun, Zhang, Yafei, Ni, Fang, Hu, Yongxian, Huang, He, Zhao, Kui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371710/ https://www.ncbi.nlm.nih.gov/pubmed/34422666 http://dx.doi.org/10.3389/fonc.2021.713577

Ejemplares similares

New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
por: Wang, Linqin, et al.
Publicado: (2021)

Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse
por: Ding, Lijuan, et al.
Publicado: (2021)

Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment
por: Zhou, Linghui, et al.
Publicado: (2021)

Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy
por: Hong, Ruimin, et al.
Publicado: (2020)

Clinical Characterization and Risk Factors Associated with Cytokine Release Syndrome Induced By COVID-19 and Chimeric Antigen Receptor T-Cell Therapy
por: Hong, Ruimin, et al.
Publicado: (2020)

The role of pre-treatment and mid-treatment 18F-FDG PET/CT imaging in evaluating prognosis of peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS)
por: Zhang, Yafei, et al.
Publicado: (2021)

Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies
por: Zhu, Feng, et al.
Publicado: (2020)

A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
por: Wang, Yiyun, et al.
Publicado: (2020)

Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma
por: Zu, Cheng, et al.
Publicado: (2022)

Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome—A Wandering Road to Remission
por: Wang, Yiyun, et al.
Publicado: (2021)

Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy
por: Zhang, Mingming, et al.
Publicado: (2021)

CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies
por: Hu, Yongxian, et al.
Publicado: (2022)

Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-cell Malignancies
por: Zhu, Feng, et al.
Publicado: (2021)

Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019
por: Zhou, Linghui, et al.
Publicado: (2021)

Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I study
por: Hu, Yongxian, et al.
Publicado: (2023)

Pleural cavity cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy: A case report
por: Ding, Lijuan, et al.
Publicado: (2018)

The role of FDG-PET in Hodgkin lymphoma
por: Subocz, Edyta, et al.
Publicado: (2017)

FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas
por: Barrington, Sally F., et al.
Publicado: (2017)

Delayed Terminal Ileal Perforation in a Relapsed/Refractory B-Cell Lymphoma Patient with Rapid Remission Following Chimeric Antigen Receptor T-Cell Therapy
por: Hu, Yongxian, et al.
Publicado: (2018)

Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats
por: André, M., et al.
Publicado: (2011)

Granulomatous Lymphangitis Masquerading as Relapsed Hodgkin Disease on FDG PET/CT
por: Mustafa, Mansour, et al.
Publicado: (2018)

Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin’s Lymphoma
por: Al-Ibraheem, Akram, et al.
Publicado: (2022)

Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction
por: Hong, Ruimin, et al.
Publicado: (2021)

Different Features of (18)F-FAPI, (18)F-FDG PET/CT and MRI in the Evaluation of Extrahepatic Metastases and Local Recurrent Hepatocellular Carcinoma (HCC): A Case Report and Review of the Literature
por: Chen, Donghe, et al.
Publicado: (2022)

Comparison of (18)F-FDG PET/CT and (68)Ga-FAPI in Spindle Cell Rhabdomyosarcoma
por: Shen, Zhihui, et al.
Publicado: (2023)

Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma
por: Zhang, Qiqi, et al.
Publicado: (2023)

Occipital Hypometabolism on FDG PET/CT Scan in a Child with Hodgkin's Lymphoma
por: Uslu Biner, Inci, et al.
Publicado: (2016)

[(18)F]FDG-PET/CT in Hodgkin Lymphoma: Current Usefulness and Perspectives
por: Kanoun, Salim, et al.
Publicado: (2018)

FDG-PET/CT for the Management of Post-Chemotherapy Residual Mass in Hodgkin lymphoma
por: Gallamini, Andrea, et al.
Publicado: (2021)

Radiomic Features of (18)F-FDG PET in Hodgkin Lymphoma Are Predictive of Outcomes
por: Zhou, Yeye, et al.
Publicado: (2021)

Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
por: Wei, Guoqing, et al.
Publicado: (2017)

Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy
por: Qiu, Lei, et al.
Publicado: (2020)

Automated quantification of baseline imaging PET metrics on FDG PET/CT images of pediatric Hodgkin lymphoma patients
por: Weisman, Amy J., et al.
Publicado: (2020)

Bilateral trigeminal nerve recurrence of non-hodgkin lymphoma revealed with FDG PET/CT
por: Yılmaz, Sabire, et al.
Publicado: (2014)

Use of (18)F FDG PET and the short temporal response of Hodgkin's disease to RIT
por: Nowosinska, Ewa, et al.
Publicado: (2018)

FDG-PET Imaging for Hodgkin and Diffuse Large B-Cell Lymphoma—An Updated Overview
por: Voltin, Conrad-Amadeus, et al.
Publicado: (2020)

Assessment of Response to Immunotherapy in Patients with Hodgkin Lymphoma: Towards Quantifying Changes in Tumor Burden Using FDG-PET/CT
por: Tutino, Francesca, et al.
Publicado: (2023)

Non-Hodgkin lymphoma of multiple extranodal involvement seen on MRI, FDG PET–CT scans: A case report
por: Wang, Shan, et al.
Publicado: (2017)

Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma
por: Naumann, R, et al.
Publicado: (2004)

Hot tongue on FDG PET scan in a patient of Hodgkin’s lymphoma undergoing antipsychotic treatment
por: Pawaskar, Alok S, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_cc7h39v9nkakd8a1dbc7vpnag6